9g7d

From Proteopedia

Crystal structure of ASGPR with bound IMP

Structural highlights

9g7d is a 1 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:	X-ray diffraction, Resolution 1.588Å
Ligands:	,
Resources:	FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

ASGR1_HUMAN Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface.

Publication Abstract from PubMed

To increase the chemical space around the well-known GalNAc-ligand as ASGPR-binder, a high-throughput screening campaign was performed, testing approximately 550,000 compounds. After evaluation of the potential screening hits, only one compound, which showed high similarity with guanosine nucleosides, was chosen for further profiling. Crystal structure analysis revealed the coordination of the Ca(2+)-ion within the ASGPR-binding site by the cis-diol motif of the ribose unit as well as an additional pi-pi-interaction of the purine heterocycle to tryptophan-243. Based on these findings, guanosine was attached via the 5'-OH group to a recently described morpholino-based nucleotide using two different linker units. The resulting morpholino-guanosine building blocks were conjugated to the 5'-end of a literature-known transthyretin targeting small interfering RNA (siRNA), leading to trivalent siRNA-guanosine conjugates, which were tested for their TTR knockdown and exhibited similar potencies as the analogous GalNAc-conjugates in vitro and in vivo.

Trivalent siRNA-Conjugates with Guanosine as ASGPR-Binder Show Potent Knock-Down In Vivo.,Hofmeister A, Jahn-Hofmann K, Brunner B, Helms M, Metz-Weidmann C, Poeverlein C, Zech G, Li Z, Hessler G, Schreuder H, Elshorst B, Krack A, Kurz M, Heubel C, Scheidler S J Med Chem. 2025 Mar 7. doi: 10.1021/acs.jmedchem.4c02275. PMID:40052708^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

↑ Hofmeister A, Jahn-Hofmann K, Brunner B, Helms M, Metz-Weidmann C, Poeverlein C, Zech G, Li Z, Hessler G, Schreuder H, Elshorst B, Krack A, Kurz M, Heubel C, Scheidler S. Trivalent siRNA-Conjugates with Guanosine as ASGPR-Binder Show Potent Knock-Down In Vivo. J Med Chem. 2025 Mar 7. PMID:40052708 doi:10.1021/acs.jmedchem.4c02275